Author: Zhichao Feng; Jennifer Li; Shanhu Yao; Qizhi Yu; Wenming Zhou; Xiaowen Mao; Huiling Li; Wendi Kang; Xin Ouyang; Ji Mei; Qiuhua Zeng; Jincai Liu; Xiaoqian Ma; Pengfei Rong; Wei Wang
Title: The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis Document date: 2020_4_10
ID: k65501xp_28
Snippet: Thirty patients were classified with severe pneumonia on admission and were excluded, to leave 534 patients with non-severe COVID-19 on admission for further analysis. Amongst this group, 39 (7.3%) patients developed severe pneumonia during hospitalization. Most (n = 503 [94.2%]) patients received single or combined antiviral therapy during their admission. After adjusting for age, gender, smoking history, hypertension, diabetes, cardiovascular d.....
Document: Thirty patients were classified with severe pneumonia on admission and were excluded, to leave 534 patients with non-severe COVID-19 on admission for further analysis. Amongst this group, 39 (7.3%) patients developed severe pneumonia during hospitalization. Most (n = 503 [94.2%]) patients received single or combined antiviral therapy during their admission. After adjusting for age, gender, smoking history, hypertension, diabetes, cardiovascular disease, COPD, and lung CT score, none of these investigational antiviral therapies (all P > 0.05) were associated with reduced risk of progression to severe disease, as shown in Table 2 .
Search related documents:
Co phrase search for related documents- admission severe pneumonia and cardiovascular disease: 1, 2
- admission severe pneumonia and non severe: 1, 2, 3, 4, 5, 6, 7, 8, 9
- admission severe pneumonia and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- admission severe pneumonia and severe pneumonia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- admission severe pneumonia and severe pneumonia develop: 1, 2
- analysis admission and antiviral therapy: 1
- analysis admission and cardiovascular disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- analysis admission and non severe: 1, 2, 3, 4, 5, 6, 7, 8
- analysis admission and reduce risk: 1, 2, 3, 4, 5
- analysis admission and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- analysis admission and severe pneumonia: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral therapy and cardiovascular disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- antiviral therapy and investigational antiviral therapy: 1, 2, 3
- antiviral therapy and non severe: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- antiviral therapy and reduce risk: 1, 2, 3, 4, 5, 6, 7, 8, 9
- antiviral therapy and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral therapy and severe pneumonia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cardiovascular disease and lung CT score: 1
- cardiovascular disease and non severe: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date